Actimed Therapeutics Ltd.
https://actimedtherapeutics.com/home/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Actimed Therapeutics Ltd.
Actimed Aims High With Cancer Cachexia Prospect
The UK firm has got the green light in the US to conduct two Phase IIb/III trials of its cancer cachexia candidate S-pindolol but a lot more money needs to be raised to complete them.
Finance Watch: Genesis, Rapport, Cellares Raise Venture Capital Mega-Rounds
Private Company Edition: Genesis raised $200m, Rapport brought in $150m and Cellares closed a $255m round. Also, Ferring got $300m up front in a royalty deal, Fore Biotherapeutics raised a $75m series D and Vaxxas won a $3.67m Wellcome grant to advance a next-generation typhoid vaccine.
Deal Watch: Gain To Test Enzyme-Enhancement Tech In Cancer With Zentalis
Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice